Literature DB >> 9288171

Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues.

Q S Yu1, X F Pei, H W Holloway, N H Greig, A Brossi.   

Abstract

N(8)-Benzylesermethole (6) was prepared from 5-methoxytryptamine (1) in five steps. Resolution of compound 6 by dibenzoyl- and ditoluyltartaric acid provided enantiomers (-)- and (+)-7. After demethylation, reaction with isocyanates and catalytic debenzylation over hydrogen, the total syntheses of (-)- and (+)-N(8)-norphysostigmine [(-)- and (+)-11] and (-)- and (+)-N(8)-norphenserine [(-)- and (+)-12] were accomplished, (-)-N(8)-Norphysostigmine [(-)-11] and (-)-N(8)-norphenserine [(-)-12] were also obtained by transformations of natural physostigmine [(-)-13] and phenserine [(-)-14] prepared from (-)-13. The absolute configurations and optical purity of compounds (-)-11, (-)-12, (+)-11, and (+)-12 were confirmed by a comparison of their optical rotations with those of the compounds synthesized from physostigmine [(-)-13]. The anticholinesterase activities of N(8)-nor- and N(8)-substituted analogues, (-)- and (+)-9, -10, -11, -12, 15, and 16, were compared with those of physostigmine [(-)- and (+)-13] and phenserine [(-)- and (+)-14] and are reported.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288171     DOI: 10.1021/jm970210v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices.

Authors:  Yue Wang; Nigel H Greig; Qian-sheng Yu; Mark P Mattson
Journal:  Neurobiol Aging       Date:  2008-02-20       Impact factor: 4.673

2.  Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergic action.

Authors:  Qian-Sheng Yu; Marcella Reale; Mohammad A Kamal; Harold W Holloway; Weiming Luo; Kumar Sambamurti; Balmiki Ray; Debomoy K Lahiri; Jack T Rogers; Nigel H Greig
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2013

3.  Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions.

Authors:  Dov Barak; Arie Ordentlich; Dana Stein; Qian-Sheng Yu; Nigel H Greig; Avigdor Shafferman
Journal:  Biochem J       Date:  2009-01-01       Impact factor: 3.857

4.  The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression.

Authors:  Sohan Mikkilineni; Ippolita Cantuti-Castelvetri; Catherine M Cahill; Amelie Balliedier; Nigel H Greig; Jack T Rogers
Journal:  Parkinsons Dis       Date:  2012-05-29

5.  (-)-Phenserine attenuates soman-induced neuropathology.

Authors:  Jun Chen; Hongna Pan; Cynthia Chen; Wei Wu; Kevin Iskandar; Jeffrey He; Tetsade Piermartiri; David M Jacobowitz; Qian-Sheng Yu; John H McDonough; Nigel H Greig; Ann M Marini
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

6.  Sequential combined Treatment of Pifithrin-α and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke.

Authors:  Flavia Turcato; Paul Kim; Austin Barnett; Yongming Jin; Mike Scerba; Anthony Casey; Warren Selman; Nigel H Greig; Yu Luo
Journal:  Cell Transplant       Date:  2018-06-05       Impact factor: 4.064

7.  Pharmacophore-based design and discovery of (-)-meptazinol carbamates as dual modulators of cholinesterase and amyloidogenesis.

Authors:  Qiong Xie; Zhaoxi Zheng; Biyun Shao; Wei Fu; Zheng Xia; Wei Li; Jian Sun; Wei Zheng; Weiwei Zhang; Wei Sheng; Qihong Zhang; Hongzhuan Chen; Hao Wang; Zhuibai Qiu
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

8.  In Silico and Ex Vivo Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes.

Authors:  Sidra Batool; Tiyyaba Furqan; Muhammad Sibte Hasan Mahmood; David Tweedie; Mohammad A Kamal; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2022-01-12

9.  Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.

Authors:  Maria L Maccecchini; Mee Young Chang; Catherine Pan; Varghese John; Henrik Zetterberg; Nigel H Greig
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-07-11       Impact factor: 10.154

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.